Citigroup Inc (TRVC)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 108.40 |
|---|---|
| 52-week range | 82.95 – 129.04 |
| Return, 1 month / 3 months | −6.7% / −5.7% |
| Return, 1 year / 3 years | +32.8% / +220.2% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 28.5% |
| Worst drawdown (1 year) | -15.5% |
| Average daily value traded | 0.10M EUR |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Citigroup is a global financial services group based in New York. It serves consumers, corporations, governments and institutions through retail banking, credit cards, corporate and investment banking, and wealth management. Its operations span many countries, with brands such as Citibank and Citi Cards serving individual customers and businesses, while its institutional arm provides financing, advisory and treasury services to large organisations and public bodies around the world.
On this site Citigroup Inc appears as a stock on the XETRA Stock Exchange (Germany), code TRVC, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Citigroup Inc (TRVC) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 108.40 on 23 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 200 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 32.8% and over the last three months it fell 5.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.5% | ||
| From 52-week high | -15.9% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -5.7% | ||
| 6-month return | -1.1% | ||
| 12-month return, skipping the last month | 42.4% | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.5% | ||
| Liquidity | 44 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 63 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.4% |
|---|---|
| 1 month | −6.7% |
| 3 months | −5.7% |
| 6 months | −1.1% |
| 1 year | +32.8% |
| 3 years | +220.2% |
| 5 years | +108.7% |
Signals
| 50-day / 200-day average | 114.63 / 108.99 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.21 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Aug 2026 | USD 0.5960 |
| 4 May 2026 | USD 0.5337 |
| 2 Feb 2026 | USD 0.5337 |
| 3 Nov 2025 | USD 0.5337 |
| 4 Aug 2025 | USD 0.5337 |
| 5 May 2025 | USD 0.4981 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.